Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali

Modibo Diarra; Drissa Coulibaly; Amadou Tapily; Boureima Guindo; Koualy Sanogo; Diakalia Koné; Youssouf Koné; Karim Koné; Aboudramane Bathily; Oumar Yattara; Mahamadou A Thera; Alassane Dicko; Abdoulaye A Djimdé; Issaka Sagara

doi:10.3390/tropicalmed6010013

Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali

Trop Med Infect Dis. 2021 Jan 24;6(1):13. doi: 10.3390/tropicalmed6010013.

Affiliations

¹ Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences Techniques and Technology of Bamako, Bamako BP 1805, Mali.
² National Malaria Control Program (PNLP-Mali), Bamako 223, Mali.
³ Populations Services International-Mali (PSI-Mali), Bamako E5397, Mali.

Abstract

In Mali, since 2007, artemether-lumefantrine has been the first choice against uncomplicated malaria. Despite its effectiveness, a rapid selection of markers of resistance to partner drugs has been documented. This work evaluated the treatment according to the World Health Organization's standard 28-day treatment method. The primary endpoint was the clinical and parasitological response corrected by a polymerase chain reaction. It was more than 99.9 percent, the proportion of patients with anemia significantly decrease compared to baseline (p < 0.001), and no serious events were recorded. Plasmodium falciparum remains sensitive to artemether-lumefantrine in Mali.

Keywords: Mali; Plasmodium falciparum; artemether-lumefantrine; in vivo efficacy; malaria.